Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB–IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study assessed treatment administration and outcomes in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Berton, Dominique, Floquet, Anne, Lescaut, Willy, Baron, Gabriel, Kaminsky, Marie-Christine, Toussaint, Philippe, Largillier, Rémy, Savoye, Aude-Marie, Alexandre, Jérôme, Delbaldo, Catherine, Malaurie, Emmanuelle, Barletta, Hugues, Bosacki, Claire, Garnier-Tixidre, Claire, Follana, Philippe, Laharie-Mineur, Hortense, Briac Levache, Charles, Valenza, Bruno, Dechartres, Agnès, Mollon-Grange, Delphine, Selle, Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489574/
https://www.ncbi.nlm.nih.gov/pubmed/34616296
http://dx.doi.org/10.3389/fphar.2021.711813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489574/
https://www.ncbi.nlm.nih.gov/pubmed/34616296
http://dx.doi.org/10.3389/fphar.2021.711813

Ejemplares similares